health care icon pattern medical innovation concept background design

health care icon pattern medical innovation concept background design

Pharmacy Industry Updates: April

View the video recap below:

 

PDMP Roundup

PDMP Reporting

  • California – Require Serial Number to be reported
    • Emergency Legislation signed which delays enforcement of the Serial Number requirements to at least 07-01-2019 and no later than 01-01-2020.
    • Allows dispensing of prescriptions on old pads until 01-01-2021
    • DOJ/BOP are still discussing the format of the serial number and barcode.
    • It does not address the PDMP reporting aspect.
  • Ohio — report Naltrexone Products to OARRS Effective 03-19-2019 (Notice on 01-16-19)
  • Florida – ASAP V4.2 Accepted now, but required as of 12-19-2019

 

Potential PDMP Changes

  • Utah — Finalized rule not yet published in the Utah Bulletin. Waiting on final details.
  • Nebraska – Pending legislation to require ASAP V4.2A and add additional fields in Q3 of 2019. Including Gender, ID, Sold date. SIG requirement will likely be removed.
  • Oregon HB 3315 –Introduced March 4, 2019, Adds to the reporting
    • method of payment used to purchase the prescription drug
    • diagnosis or other information related to a prescription
    • Whether the patient is required to obtain prescriptions from a designated practitioner or prescription drugs from a designated pharmacy

 

PDMP Checking

  • Montana – Updated rules on checking PDMP data prior to prescribing or dispensing 10-01-2019

The following states have recently announced state-wide funding for Appriss Health’s PMP Gateway and/or NarxCare solutions:

  • Alabama: Funding NarxCare
  • Louisiana: Funding NarxCare
  • Nevada: Funding NarxCare
  • Washington D.C.: Funding Gateway

 

Legislative/Regulatory Reminders for March/April  2019

 

  • Medicare Part D – Precluded Provider Implementation on 04-01-2019
    • The affected providers (pharmacies and prescribers) should have been notified by CMS and should not be on  the list until all appeals to this process were exhausted.
    • The CMS Precluded Provider list is not publicly available.
    • Any affected beneficiaries should have gotten at least a 60 day notice.
    • This is NOT something that can be overridden during adjudication.
    • Expect Reject Code 929- ID Submitted is associated with a precluded prescriber.

 

  • Alabama – Updates regulations for:
    • Supervising pharmacists
    • Failing to complete Continuing Education
  • Idaho – Myriad of Rules in April if Legislature Approves  — See March BOP Newsletter for summary.
  • Texas – Updated rules related to licensing and pharmacy practice
  • Wyoming – Prohibit Gag Orders

 

New Legislative/Regulatory Highlights   

  • Arkansas – Require electronic prescribing on Schedule II through VI as of 01-01-2021
  • Arizona – Delayed EPCS for Schedule II Opioids until 01-01-2020, with some exceptions.
  • Nebraska – Requires coverage for filling prescriptions to synchronize the patient’s medications with prorated copays and full dispensing fees.
  • South Dakota – Prohibit gag orders
  • Virginia – Gabapentin has moved from a drug of concern to Schedule V (Immediate)
  • Wyoming – Require EPCS as of 01-01-2021

 

Get Involved/Get Informed Spotlight

 

Monthly Opioid Updates

 

PBM’s and Medicaid Updates

  • Washington Medicaid and below cost dispensing fees
    • NACDS and NAPB filed briefs requesting immediate action including retroactive payment back to April 1, 2017.
  • More states taking on PBMS and spread pricing for Medicaid Managed Care
    • Kentucky, Montana, New Jersey, New York, Ohio, South Dakota, Tennessee, Texas, West Virginia

 

Rules, Rules, and more Rules

Contact us to ask questions or get more information about these updates.

Bio and photo of Leann Lewis

Disclaimer:

The organizer of this call is not an attorney, and the presentation on this call does not constitute legal advice.  It contains only the opinions and observations of the organizer and its participants.  Any use of information contained in this presentation is at the user’s own risk. The organizer will not be available for depositions or testimony in case of litigation.

Leave a Reply

Your email address will not be published. Required fields are marked *